Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Emergent Biosolutions Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EBS
New York
2834
https://emergentbiosolutions.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Emergent Biosolutions Inc
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
- Apr 22nd, 2024 12:05 pm
Institutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year losses
- Apr 17th, 2024 2:44 pm
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
- Apr 1st, 2024 12:00 pm
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
- Mar 28th, 2024 12:15 pm
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
- Mar 25th, 2024 12:05 pm
Emergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results
- Mar 7th, 2024 6:58 pm
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
- Mar 7th, 2024 5:34 pm
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 3:33 pm
Q4 2023 Emergent BioSolutions Inc Earnings Call
- Mar 7th, 2024 12:35 pm
Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 4:30 am
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
- Mar 6th, 2024 10:55 pm
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
- Mar 6th, 2024 9:31 pm
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
- Feb 29th, 2024 12:00 pm
UPDATE 2-Emergent appoints former Bausch + Lomb CEO to head company
- Feb 21st, 2024 12:35 pm
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
- Feb 21st, 2024 12:00 pm
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
- Feb 13th, 2024 9:45 am
Emergent extends shelf life of opioid overdose reversal drug Narcan
- Jan 17th, 2024 4:55 pm
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
- Jan 12th, 2024 7:20 pm
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
- Jan 11th, 2024 1:00 pm
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
- Jan 9th, 2024 12:30 pm
Scroll